Search Results for: 99

— Data Analysis Did Not Demonstrate Statistically Significant Differences Between Treatment and Placebo Groups — ROCKVILLE, Md., Feb. 2, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, today reported independent third party analysis of the investigator-sponsored Phase 2 clinical trial that evaluated […]

ROCKVILLE, Md., Jan. 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeff Riley, CEO, is scheduled to present at the Biotech Showcase™ 2016 Conference next week in San Francisco, as follows: Date: Monday, January 11, 2016Time: 11:00 a.m.

— Adds to Existing International Patent Estate Directly Related to SYN-010 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Nov. 24, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting

ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Achieved Planned Milestones for Company’s Lead Microbiome Drug Candidates Enhanced Senior Management Team to Maximize Strategic Opportunities Strengthens Balance Sheet to Support Microbiome Clinical Trials Conference Call Today, August 10, 2015, at 8:30 a.m. EDT Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to

ROCKVILLE, Md., July 15, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by

— Data Supporting Development of Expanded C. difficile Preventive Therapeutics also Accepted for Presentation — ROCKVILLE, Md., April 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004,

— Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman — ROCKVILLE, Md., Oct. 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, announced today the expansion of its Clinical Advisory Board (CAB) created to support

— Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 — — Conference Call Today, August 14, 2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224 — ROCKVILLE, Md., Aug. 14,

— Company Expects to Initiate C. difficile Clinical Trials in 2014 — ROCKVILLE, Md., June 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of

— Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and